Protective Effects of the mTOR Inhibitor Everolimus on Cytoskeletal Injury in Human Podocytes Are Mediated by RhoA Signaling

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Jeruschke, Stefanie ^a   Büscher, Anja Katrin ^a   Oh, Jun ^b   Saleem, Moin Ahson ^c   Hoyer, Peter Friedrich ^a   Weber, Stefanie ^a   Nalbant, Perihan ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHANOL; MYOSIN LIGHT CHAIN; PROTEIN KINASE; PUROMYCIN AMINONUCLEOSIDE; RHO ASSOCIATED PROTEIN KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ARTICLE; CELL ADHESION; CELL DAMAGE; CELL FUNCTION; CELL MIGRATION; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PODOCYTE; PROTEINURIA; SIGNAL TRANSDUCTION; STRESS FIBER;

APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CYTOSKELETON; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PODOCYTES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SIROLIMUS; STRESS FIBERS;

EID: 84873911064     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055980     Document Type: Article

References (59)

1. Benzing T, (2004) Signaling at the slit diaphragm. J Am Soc Nephrol 15: 1382-1391.
2. Whiteside CI, Cameron R, Munk S, Levy J, (1993) Podocytic cytoskeletal disaggregation and basement-membrane detachment in puromycin aminonucleoside nephrosis. Am J Pathol 142: 1641-1653.
3. Etienne-Mannville S, Hall A, (2002) Rho GTPase in cell biology. Nature 420: 629-635.
4. Bishop AL, Hall A, (2000) Rho GTPases and their effector proteins. Biochem J 348: 241-255.
5. Burridge K, Chrzanowska-Wodnicka M, (1996) Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 12: 463-518.
6. Schwartz M, (2004) Rho signalling at a glance. J Cell Sci 117: 5457-5458.
7. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, et al. (1997) Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 275: 1308-1311.
8. Chrzanowska-Wodnicka M, Burridge K, (1996) Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol 133: 1403-1415.
9. Ivanov AI, (2008) Actin motors that drive formation and disassembly of epithelial apical junctions. Front Biosci 13: 6662-6681.
10. Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K, et al. (2006) Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 8: 485-491.
11. Wang L, Ellis MJ, Gomez JA, Eisner W, Fennell W, et al. (2012) Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int 81: 1075-1085.
12. Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, et al. (2011) Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121: 2197-2209.
13. Hresko RC, Mueckler M, (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280: 40406-40416.
14. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
15. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128.
16. Vollenbröker B, George B, Wolfgart M, Saleem MA, Pavenstädt H, et al. (2009) mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 296: F418-F426.
17. Inoki K, (2008) Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res Clin Pract 82: S59-S62.
18. Yost SE, Byrne R, Kaplan B, (2011) Transplantation: mTOR inhibition in kidney transplant recipients. Nat Rev Nephrol 7: 553-555.
19. Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E, (2004) Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 17: 215-220.
20. Butani L, (2004) Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 78: 1362-1366.
21. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, et al. (2004) Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4: 1869-1875.
22. Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, et al. (2010) Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 23: 1084-1093.
23. Büchler M, Caillard S, Barbier S, Thervet E, Toupance O, et al. (2007) Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 7: 2522-2531.
24. Budde K, Becker T, Arns W, Sommerer C, Reinke P, et al. (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377: 837-847.
25. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, et al. (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 9: 1115-1123.
26. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, et al. (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87: 233-242.
27. Roodnat JI, Mulder PG, Rischen-Vos J, van Riemsdijk IC, van Gelder T, et al. (2001) Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 72: 438-444.
28. Daniel C, Ziswiler R, Frey B, Pfister M, Marti HP, (2000) Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 8: 52-62.
29. Ito N, Nishibori Y, Ito Y, Takagi H, Akimoto Y, et al. (2011) mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome. Lab Invest 91: 1584-1595.
30. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, et al. (2002) A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638.
31. Kummer S, Jeruschke S, Wegerich LV, Peters A, Lehmann P, et al. (2011) Estrogen Receptor Alpha Expression in Podocytes Mediates Protection against Apoptosis In-Vitro and In-Vivo. PLoS One 6: e27457.
32. Yan K, Ito N, Nakajo A, Kurayama R, Fukuhara D, et al. (2012) The struggle for energy in podocytes leads to nephrotic syndrome. Cell Cycle 11: 1504-1511.
33. Reiser J, Oh J, Shirato I, Asanuma K, Hug A, et al. (2004) Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 279: 34827-34832.
34. Gallegos L, Ng MR, Brugge JS, (2011) The myosin-II-responsive focal adhesion proteome: a tour de force? Nature Cell Biology 13: 344-346.
35. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM, (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95: 1432-1437.
36. Nobes CD, Hall A, (1995) Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81: 53-62.
37. Ridley AJ, Hall A, (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389-399.
38. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, et al. (1996) Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271: 20246-20249.
39. Totsukawa G, Wu Y, Sasaki Y, Hartshorne DJ, Yamakita Y, et al. (2004) Distinct roles of MLCK and ROCK in the regulation of membrane protrusions and focal adhesion dynamics during cell migration of fibroblasts. J Cell Biol 164: 427-439.
40. Ichimura K, Kurihara H, Sakai T, (2003) Actin filament organization of foot processes in rat podocytes. J Histochem Cytochem 2003 51: 1589-1600.
41. Mundel P, Shankland SJ, (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13: 3005-3015.
42. Mundel P, Reiser J, Kriz W, (1997) Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 8: 697-705.
43. Kretzler M, (2002) Regulation of adhesive interaction between podocytes and glomerular basement membrane. Microsc Res Tech 15 57: 247-253.
44. Gardel ML, Schneider IC, Aratyn-Schaus Y, Waterman CM, (2010) Mechanical integration of actin and adhesion dynamics in cell migration. Annu Rev Cell Dev Biol 26: 315-333.
45. Kerjaschki D, (2001) Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 108: 1583-1587.
46. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, et al. (2009) Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol 296: F213-F229.
47. Eto N, Wada T, Inagi R, Takano H, Shimizu A, et al. (2007) Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 72: 455-463.
48. Ransom RF, Lam NG, Hallett MA, Atkinson SJ, Smoyer WE, (2005) Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 68: 2473-2483.
49. Fuchshofer R, Ullmann S, Zeilbeck LF, Baumann M, Junglas B, et al. (2011) Connective tissue growth factor modulates podocyte actin cytoskeleton and extracellular matrix synthesis and is induced in podocytes upon injury. Histochem Cell Biol 136: 301-319.
50. Bershadsky AD, Balaban NQ, Geiger B, (2003) Adhesion-dependent cell mechanosensitivity. Annu Rev Cell Dev Biol 19: 677-695.
51. Kriz W, Gretz N, Lemley KV, (1998) Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 54: 687-697.
52. Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser IA, et al. (2005) Mechanisms of everolimus induced glomerulonephritis after glomerular injury in the rat. Am J Transplant 5: 2849-2861.
53. Markova B, Hähnel PS, Kasper S, Herbertz S, Schuler M, et al. (2012) Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. J Cancer Res Clin Oncol 138: 545-554.
54. Welsh GI, Saleem MA, (2011) The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat Rev Nephrol 8: 14-21.
55. Van Aelst L, D'Souza-Schorey C, (1997) Rho GTPases and signaling networks. Genes Dev 11: 2295-2322.
56. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, et al. (2001) Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 12: 413-422.
57. Zhou H, Huang S, (2010) The complexes of mammalian target of rapamycin. Curr Protein Pept Sci 11: 409-424.
58. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, et al. (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 14: 931-938.
59. Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA, (2010) RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem 109: 320-328.